SATURDAY | NOV. 16, 2024 Daily News Challenged by rare cardiomyopathies Session offers new insights and management strategies. Cardiologists are well versed in treating cardiomyopathies. But understanding the mechanisms underlying the conditions and alterations in cardiac structure and function — as well as diagnostic tools — remains a challenge. Kevin Alexander, MD, is among the speakers taking a deeper look at those challenges Saturday afternoon in “New Insights Into Cardiomyopathies That Plague the Cardiologist.” Alexander is an advanced heart failure and transplant cardiologist and member of the Stanford Amyloid Center at Stanford University in California. “Treating cardiomyopathies is an area where precision medicine is becoming a reality,” said Alexander, assistant professor of cardiovascular medicine at Stanford University. “Historically, our approach to heart failure in general is using a standard set of medications, such as beta blockers and aldosterone antagonists, which may not directly treat the various underlying cause of cardiomyopathies. “As we’ve gotten more understanding of genetic and infiltrative cardiomyopathies, like amyloid and hypertrophic cardiomyopathy, treatments specifically for these underlying subtypes have been developed. So, I think that that has the potential for improved clinical outcomes for many heart failure patients.” One challenge is to continue to tailor therapies to treat the underlying cause of cardiomyopathy, he said. Another is how to accurately measure treatment response. Advances have been made in multimodality imaging using MRI, nuclear scans and CT. Both imaging and blood-based biomarkers need further development to assess patient outcomes, he said. Alexander uses cardiac amyloidosis as an example when describing the challenges. See CARDIOMYOPATHIES, page 6 Today’s Late-Breaking Science and Featured Science 3 Aspirin’s staying power 5 Research Goes Red recognition: Q&A with awardee Silvi Shah, MD, MS 11 Distinguished Scientists 12-15 Exhibitors and Science & Technology Hall map 8-10 #AHA24 UPCOMING SESSION New Insights Into Cardiomyopathies That Plague the Cardiologist 3:15-4:30 p.m. | Saturday, Nov. 16 S102BC Alexander Adigun Welcome to Chicago! The AHA Scientific Sessions 2024 commenced yesterday with pre-session symposia and early career programming. Designed to inspire and educate, the events featured a blend of cardiovascular science and networking opportunities. Highlights included QCOR programming as well as a QCOR Career Development Roundtable and Networking Luncheon, connecting early career professionals with leaders in the QCOR community. Symposia delved into critical topics, such as emerging therapies for heart disease and chronic kidney disease. Other programs offered recommendations for discovering a research path and developing research products. Friday’s focus also included a global spotlight with three symposia on Global Opportunities to Advance Health and Hope. These events underscored AHA’s commitment to advancing science and nurturing the next generation of leaders in cardiovascular health. Where Our History Meets Our Future Don’t miss the American Heart Association’s Centennial Experience! This exhibit marks 100 years of achievements in fighting heart disease — and explores how together we can tackle the next century of challenges. Located in the Grand Concourse adjacent to Registration. Inside
3 #AHA24 ScientificSessions.org Today at Sessions Late-Breaking Science LBS.01: Celebrating a Century of Cardiovascular Science: From Prevention to Treatment, to Cure 8:30-9:45 a.m. | Main Event I • Effects of Intensive Blood Pressure Control in Patients With Type 2 Diabetes (BPROAD) • Tirzepatide for Patients With Heart Failure With Preserved Ejection Fraction and Obesity: the SUMMIT Trial • Nexiguran Ziclumeran (nex-z, also known as NTLA-2001), an Investigational in Vivo CRISPRBased Therapy for Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM): Interim Report of the Phase 1 Study LBS.02: Redefining Arrhythmia Treatment: Pushing Boundaries 1:30-2:45 p.m. | Main Event I • Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia in Ischemic Cardiomyopathy (VANISH2) • Randomized Comparison of Left Atrial Appendage Closure With Oral Anticoagulation After Catheter Ablation for Atrial Fibrillation (OPTION) • Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN AF) LBS.03: Smart Cardiology: Harnessing AI and Innovation for Better Heart Health 3:15-4:30 p.m. | Main Event I • Evaluation of Randomized Audit and Feedback to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Health Care System (PHARM-HF A&F Study) • Novel AI to Assess Intracardiac Filling Pressure: The Noninvasive SEISMocardiogram in Cardiovascular Monitoring for Heart Failure I (SEISMIC-HF I) Study • Artificial Intelligence-Based Automated ECHOcardiographic Measurements and the Workflow of Sonographers (AI-ECHO): Randomized Crossover Trial • PanEcho: Complete AIenabled Echocardiography Interpretation With Multitask Deep Learning Featured Science FS.01: Novel Approaches to Managing Lipid Risk 1:30-2:45 p.m. | S100A • Long-Term Efficacy of Lerodalcibep in 1,468 Patients at Very High and High Risk for CVD in the 72-Week Open-Label Extension Trial (LIBerate-OLE) • Efficacy and Safety of Lerodalcibep, a ThirdGeneration PCSK9 Inhibitor, in 703 Heterozygous Familial Hypercholesterolemia Subjects in the Open Label Extension Trial (LIBerate-HeFH_OLE) • PALISADE: A Phase 3 Study to Assess the Efficacy and Safety of Plozasiran in Adults With Genetically or Clinically Defined Familial Chylomicronemia Syndrome (FCS) at High Risk of Acute Pancreatitis (AP) • Transcriptomic Signatures and Predictors of Evolocumab Added to Maximum Statin Therapy Based on Intra-Coronary Plaque Characteristics: YELLOW III Study FS.02: Health Technology and the Future of Clinical Trials 1:30-2:45 p.m. | S104B • Natural Language Processing to Adjudicate Heart Failure Hospitalizations in Global Clinical Trials (DELIVER) • Manual vs. AI-Assisted Clinical Trial Screening Using LargeLanguage Models (MAPS-LLM) • Personalized App-Based Coaching Improves Physical Activity in Patients With HFpEF Compared to Standard Care: A Randomized Parallel Group Trial (MyoMobile Study) • Impact of TechnologyEnabled Home-Based Cardiac Rehabilitation on Functional Status and Cardiovascular Health Metrics: The American Heart Association Health Technology Network mTECHRehab Randomized Controlled Trial (mTECH-Rehab) Welcome to Scientific Sessions 2024 in Chicago, where you will find the best in cardiovascular science and medicine. Main Events Generative AI in Cardiovascular Health: A Transformative Force 10-11:15 a.m. | Saturday, Nov. 16 | Main Event I Update on CV Disorders That Disproportionately Affect Women 1:30-2:45 p.m. | Saturday, Nov. 16 | Main Event II Fellowship of the Ring: Atrial Fibrillation and Heart Failure, a Collaborative Journey Through the New Middle Earth 3:15-4:30 p.m. | Saturday, Nov. 16 | Main Event II Don’t miss ... Simulation Zone | Heart Hub Cardiogenic Shock Masterclass: For those interested in taking a deep dive into aspects of diagnosis and management. Sign up for the 2-4 p.m. Masterclass. Each class runs for 60 minutes. Timeslots for Sunday and Monday are also available. Annual Dr. Nanette K. Wenger Research Goes Red® Award for Best Scientific Article on Cardiovascular Disease and Stroke in Women 9:45-11 a.m. | S100A Scan the QR code for the full schedule of Late-Breaking Science and Featured Science sessions. Use #AHA24 to share your highlights and join the conversation online. Scan the QR code to view the Industry Programming Guide. Meet the Trialist MTT.01: nex-Z and BPROAD* 3:15–4 p.m. | Overflow Theater 2, North Building, Level 2
4 SCIENTIFIC SESSIONS DAILY NEWS | Day 1 Saturday, Nov. 16, 2024 Scientific Sessions Daily News is produced for the American Heart Association for Scientific Sessions by Ascend Media, LLC (ascendmedia.com). After you have read this issue of Scientific Sessions Daily News, please share with colleagues or deposit it in an approved paper recycling bin. ©2024 by the American Heart Association 7272 Greenville Ave. Dallas, TX 75231 214-570-5935 ScientificSessions.org The American Heart Association (AHA) marks an historic landmark this year: its 100th anniversary! A wide range of celebratory events is planned to commemorate this important anniversary, to catalog, celebrate and honor the AHA’s 100-year-long journey. This is a time to recognize and honor the AHA’s numerous successes and enormous influence. Beyond that, many are working to envision and sculpt the next 100 years of AHA influence and impact. As part of this exciting yearlong celebration, AHA journals are launching a series of short articles termed Centennial Collection. Visit www.ahajournals.org/ centennial for a full listing of Centennial Collection articles and more. New: 100 Years of Lifesaving Work and Counting: Happy Birthday to the American Heart Association Highlights from the Centennial Collection The American Heart Association Journals Centennial Collection • Joseph A. Hill, MD, PhD, and on behalf of the editors-in-chief of the American Heart Association Journals CEO Foreword: The Centennial Presidential Advisory • Nancy Brown, AHA CEO Cardiology: A Century of Progress • Eugene Braunwald, MC, MACC The Feminine Face of Heart Disease 2024 • Nanette K. Wenger, MD, MACC, MACP, FAHA Visit us at BOOTH #1112 NewAmsterdam Pharma is dedicated to Defusing the LDL-C Threat © NewAmsterdam Pharma B.V. 2024. 09/24 UM---0004 NewAmsterdam Pharma recognizes the need for alternative pharmacologic approaches to LDL-C management and is committed to developing novel, nonstatin, oral therapies that will potentially reduce patients’ ASCVD risk. Paid Advertisement ASCVD, atherosclerotic cardiovascular disease; CVD, cardiovascular disease; LDL-C, low-density lipoprotein cholesterol. Reference: 1. Tsao CW, Aday AW, Almarzooq ZI, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93-e621. IT’S TIME TO EXPECT MORE Each day >2500 US adults die of CVD,1 despite available therapies Scan to learn more Remember to wear red on Sunday and Go Red For Women®. Show your support and connect with colleagues and patients nationwide who share your commitment to prevent heart disease and stroke. Wear Red Day Sunday, Nov. 17 Centennial Collection AHA marks its 100 years with journal articles highlighting its 100 years of lifesaving work.
5 #AHA24 ScientificSessions.org Lp(a) Toolkit for Healthcare Professionals High levels of plasma lipoprotein(a) (Lp(a)) are independently associated with atherosclerotic cardiovascular disease (ASCVD) and increased risk of myocardial infarction, peripheral arterial disease, and stroke. Learn more in this toolkit for healthcare professionals. Lp(a) Survey for Healthcare Professionals We invite you to take part in a brief survey designed to assess your knowledge of Lp(a) and help us understand your practice. Your responses will help the American Heart Association shape future educational activities that drive further awareness of Lp(a) screening and overall ASCVD risk management. Novartis is proud to support the American Heart Association’s Lp(a) Awareness and Testing Initiative. Find out how Lp(a) impacts your patients Lifelong Learning is a trademark of the AHA. Unauthorized use prohibited. WF650001 10/24 Paid Advertisement WF_650001_IPPC_PPD_date_Jr_Print_Ad_03kk.indd 1 10/8/24 11:31 AM Aspirin’s staying power Will newer treatments become the go-to antiplatelet therapy? For antiplatelet therapies, aspirin has been the gold standard for decades. But in recent years, other treatments, such as P2Y12 receptor inhibitors (ticlopidine, clopidogrel, ticagrelor, prasugrel), have made inroads amid a growing push toward keeping patients on antiplatelet treatments for shorter periods. Carlo Patrono, MD, FESC, said newer generations of stents designed using polymer materials have reduced the risk of coronary atherothrombosis, so the duration needed for antiplatelet treatment is shorter. That’s why P2Y12 blocker treatments are beginning to rise in popularity — they can be used when stopping dual antiplatelet therapy after PCI, especially in patients at higher risk for bleeding. Patrono, an adjunct professor of pharmacology at the Catholic University School of Medicine in Rome, will be one of several speakers discussing the past, present and future of antiplatelet therapy in Saturday’s session, “Blood Fuels the Heart: The Discovery, Development and Future of Antiplatelet Therapy in Cardiovascular Disease.” Despite the availability of newer treatments, Patrono said he believes aspirin is here to stay because no other treatment has been deemed superior by the Food and Drug Administration or the European Medicines Agency. “There is a disproportionate marketing and publishing pressure behind the newer P2Y12 inhibitors compared to aspirin that may eventually tilt the balance between the unfashionable old and the fashionable new,” he said. “Novel antiplatelet agents targeting a different pathway of platelet activation and aggregation may well come along in the near future, but they are likely to be developed on top of aspirin because of its established efficacy and safety record.” Aspirin has survived as a firstchoice antiplatelet drug 125 years after its initial marketing as an analgesic and anti-inflammatory agent, and Patrono said it isn’t going away any time soon for several reasons. “First, it has a unique mechanism of action that, together with simple pharmacokinetics, makes aspirin ideally suited to act as an antiplatelet agent,” he said. “The second factor is the discovery of a mechanism-based biomarker for dose-finding studies in health and disease that guided the choice of the right dose to maximize efficacy and minimize toxicity,” he said. “The third factor is the unusual clinical development of low-dose aspirin driven by the medical/scientific community and characterized by a very large number of investigatorinitiated, randomized clinical trials spanning the whole cardiovascular risk continuum.” In fact, Patrono said ongoing research has shown that aspirin may have new uses far beyond acting as a cardioprotective treatment. The medical community cannot underestimate “the importance of independent clinical research that was responsible for the development of low-dose aspirin as a lifesaving antithrombotic agent,” he said, “and is currently driving its evaluation in the prevention of cancer initiation and progression.” Other speakers scheduled to take part in the session are Barry Coller, MD, David Rockefeller professor of medicine at Rockefeller University in New York City, and Haydar Satar Ali, MD, a fellow at Emory University Hospital in Atlanta. UPCOMING SESSION Blood Fuels the Heart: The Discovery, Development and Future of Antiplatelet Therapy in Cardiovascular Disease 1:30-2:45 p.m. | Saturday, Nov. 16 S401A-C Patrono
6 SCIENTIFIC SESSIONS DAILY NEWS | Day 1 Saturday, Nov. 16, 2024 “This is a condition where protein buildup in the heart makes it thicker and stiffer over time, and the heart eventually fails,” he said. Historically, physicians would diagnose the condition with heart biopsy, an invasive procedure that not every center has the expertise to perform. “Fortunately, in recent years, there has been rapid and widespread adoption of a nuclear scan as a noninvasive diagnostic alternative to avoid the biopsy in many cases,” he said. “This allows us to screen more patients because it’s safe and more centers have access to this test.” However, more work needs to be done to raise awareness of amyloidosis and ensure diagnostic and treatment access in underserved areas, he said. Rosalyn O. Adigun, MD, PharmD, advanced heart failure and imaging cardiologist at the Mayo Clinic in Rochester, Minnesota, will also present at the session. Adigun said she believes gaps in knowledge and level of awareness have hindered the ability of providers to identify some of the uncommon cardiomyopathies they may encounter. “Most clinicians learn about these ‘rare’ disorders in medical school and then are far removed from them based on where they may practice,” said Adigun, who is also an assistant professor of medicine at Mayo Clinic College of Medicine and Science. “Because of this, there is often a distance between learning about these cardiomyopathies and seeing them in practice. The heterogenous presentation of some of these disorders can unfortunately also limit the ability of some providers to recognize them earlier in the disease course before patients develop systemic involvement and end-organ dysfunction.” Over the last few years, professional medical organizations have provided expert consensus statements, developed centers of excellence and increased patient outreach to increase public awareness, she said, highlighting red-flag symptoms, patterns or associations of disease and heterogenous presentations. Additionally, patient advocacy groups have provided educational resources to patients, family members and caregivers to help them identify and improve access to local resources and ongoing research trials. Cardiologists continue to raise awareness within their specialty, including clinicians, physician assistants and nurse practitioners who are often the first to see these patients. There has also been a strong emphasis, through clinical practice guidelines, for example to reflect evolving knowledge on these rare cardiomyopathies and the role of family histories and genetic testing to identify some cardiomyopathies earlier. These efforts continue to improve the work of identifying these cardiomyopathies earlier. Influential guidelines include the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines; the 2024 AHA/ACC/AMSSM/ HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy: A Report of the American Heart Association/ American College of Cardiology Joint Committee on Clinical Practice Guidelines; Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings and expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. Early identification and intervention have been shown to influence outcomes, she said. In addition, although scientists have made progress in understanding the molecular basis of most cardiomyopathies, there’s much still to learn about how and why specific cardiomyopathies can often present differently in different patients, Adigun said. Limited therapeutic options add to the challenge as well, she said, calling the problem “complex and layered,” Adigun said. There is a tendency Connect to submission guidelines, policies, and more. The new AHA Scientific Journals’ Author Hub is designed to simplify the publishing process. These comprehensive resources offer clear guidance every step of the way, Publishing in AHA Scientific Journals is synonymous with quality, relevance, and importance. Our Editors and expert peer reviewers ensure your work is accurate, significantly improves medical knowledge, and/or offers better ways to treat cardiovascular and cerebrovascular disease. AHA Scientific Journals are committed to publishing high-quality research and upholding accepted standards of methodological rigor, reproducibility, and transparency. Find out about the policies and guidelines required for a successful publication in the AHA Scientific Sessions. Publish Proudly Editorial Policies Submit Today Find Out More NEW Author Hub 4-P121 Advertisement CARDIOMYOPATHIES continued from page 1
7 #AHA24 ScientificSessions.org for the medical community — from physicians and physician-scientists to pharmaceutical companies — to look toward diseases with effective therapies or interventions for patients and have a subconscious desire to focus efforts in those areas. In rare cardiomyopathies, the picture is further complicated because fewer patients have been identified, resulting in less data to rely on. Creating well-designed interventional trials is another challenge, she said. Hurdles include an evolving knowledge of the natural history of these cardiomyopathies; pace of developing validated fit-forpurpose diagnostic tools specific for these conditions; evolving diagnostic algorithms; lack of disease-centric endpoints for clinical trials; and limited interest in investing to advance the science in rare diseases. Nevertheless, Adigun noted several management strategies to improve outcomes for cardiomyopathies. They include: • Enhanced screening and surveillance in at-risk populations, providing the opportunity to continue educating patients and health care professionals • Disease-modifying therapies or other interventions, when available • Symptom management and prevention of disease-related complications Like Alexander, Adigun said she believes cardiology is seeing great strides in precision medicine and, although this will affect management of diseases generally, the impact will be more evident in rare cardiomyopathies. Advances in genome sequencing, evolution of cardiac imaging modalities and novel work in creating in-vitro and exvivo models of disease can improve understanding of the molecular underpinnings of disease and identify better targets for interventions, she said. “With genomic sequencing, we can now identify more cardiovascular diseases that have a defined inheritance pattern caused by single genetic variant compared to other common cardiovascular diseases characterized by accumulation of small genetic variants with different implications,” Adigun said. “Identifying these variants and their weighted implications for disease manifestations are informing research in genome editing modalities in inherited cardiomyopathies, with encouraging data in early phase studies.” Join us in celebrating the 100th year of the American Heart Association by igniting the future of science! Your donation fuels groundbreaking innovation and discovery, helping us continue our mission to fight heart disease and stroke. Every contribution counts. Let’s make history! Scan the QR code to make a difference. *Donate $100 or more and select a free gift from the on-site Shop Heart store located in the registration area. IGNITE THE FUTURE
2502 2512 Posters Zone 2 Moderated Digital Posters 6-11 201 Public Service 1 2 12 320 Puppy Snuggles Supported by Sanofi 323 324 326 327 328 331 423 424 426 427 521 Bayer 526 Bridgebio 531 Eli Lilly and Company 702 Duke Clinical Research Institute 706 708 710 712 BMS/ Pfizer 716 Mayo Clinic 902 Bristol Myers Squibb 909 Intermountain Health 914 917 Merck & Co., Inc. 921 1109 Boehringer Ingelheim/Lilly Commercial 1112 New Amsterdam Pharma 1115 Pfizer, Inc. 1119 ZOLL Medical Corporation 1123 Medtronic 1302 Novartis Pharmaceuticals Corporation 1308 Novartis Pharmaceuticals Corporation 1312 Cytokinetics 1316 AstraZeneca 1322 Merck & Co., Inc. 1702 Esperion Therapeutics 1705 Idorsia Pharmaceuticals US Inc. 1708 1710 1714 1717 Arrowhead Pharmaceuticals 1720 1721 1808 1809 1820 1821 1902 Johnson & Johnson 1912 Amgen 1920 1921 1924 Amarin Pharma, Inc. 2020 2021 2022 2109 Silence Therapeutics 2120 2122 2220 2224 Kiniksa Pharmaceuticals 2302 Novo Nordisk, Inc. 2308 2309 2310 2312 2313 2315 2316 2318 Amgen 2321 Alnylam Pharmaceuticals 2408 2409 2410 2412 2413 2415 AtriCure 2514 BMS/J&J Alliance 2517 American College of Cardiology 2520 Viatris 2526 2527 2528 2531 2532 2533 2534 2712 2713 2714 2715 2717 2718 2719 2720 2721 2812 2813 2814 2815 2817 2818 2819 2820 2821 2222 806 808 809 Posters Zone 1 Moderated Digital Posters 1-5 CardioTalk Theater I Eli Lilly and Company DOWN UP UP Best of Specialty Conferences Posters Down to Level 2.5 ENTRANCE Information Counter/ Concierge Mobile App Desk Poster Attendant Booth GRAND CONCOURSE rd reet afe Global Quality Showcase HeartQuarters Heart Theater I FIRST AID FedEx Kinkos Business Center TO MAIN EVENT I Exhibit Hall Concierge Desk B39 B40 B41 B42 1909 2009 2010 Be sure to visit the Posters: Located within the Science & Technology Hall, posters are grouped into four zones by subject matter plus a fifth zone dedicated to Best of Specialty Conferences posters. Moderated digital posters are located in each poster area. Check the Mobile Meeting Guide app for the schedule. Coffee and Tea Breaks Stop by for a complimentary coffee or tea at one of the stations located within the Science & Technology Hall.
Posters Zone 4 Moderated Digital Posters 17-23 3468 Posters Zone 3 Moderated Digital Posters 12-16 3 4 5 6 Simulation Zone 8 9 10 11 13 14 3072 AHA Scholars’ Posters Supporting Undergraduate Research Experiences (S.U.R.E.) Program 15 16 537 Daiichi Sankyo, Inc. 541 Getting to the Heart of Stroke 2542 Novo Nordisk, Inc. 2550 CardioTalk Theater II 2739 Lexicon Pharmaceuticals, Inc. 2754 Lp(a) Testing Supported by Novartis Pharmaceuticals Corporation HEART HUB HIPods 1-3 HIPods 4-6 Health Innovation Pavilion STAGE UP UP UP NCY EXIT EMERGENCY EX Charging Lounge Supported by Eli Lilly and Company Member Lounge Learning Studio I Learning Studio II FAHA Lounge Heart Theater II Abstracts on USB Supported by Lexicon 7 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 B25 B27 B28 B31 B34 Exhibitor Lounge/ Sales Office B35 Business Suites B26 B30 B36 B48 B45 B41 B42 B47 B46 Publisher's Row 2939 2942 2943 2945 Wolters Kluwer 2951 2952 3042 3043 3051 3052 3139 3140 3141 3142 3143 3145 3151 3152 3239 3240 3241 3242 3243 3251 3252 2654 2557 Rocket Pharmaceuticals, Inc. Dedicated IT 2554 Explore these useful learning and networking opportunities. Science & Technology Hall South Hall, Level 3 Hours: Saturday, Nov. 16 9 a.m.-4:30 p.m. Sunday, Nov. 17 9 a.m.-4:30 p.m. Monday, Nov. 18 9 a.m.-3 p.m.
2024 Exhibitors Abcentra . . . Health Innovation Pavilion, B46 AccurKardia . . . . Health Innovation Pavilion ADInstruments . . . . . . . . . . . . .2021 Agepha Pharma FZ-LLC . . . . . . . . . 2220 AliveCor . . . . . . Health Innovation Pavilion Alnylam Pharmaceuticals . . . . . . .2321,B1 ALZET® Osmotic Pumps/DURECT Corp . . .2410 Amarin Pharma, Inc. . . . . . . . . . . 1924 American Association of Heart Failure Nurses . 2814 American College of Cardiology . . . . . 2517 American College of Physicians/ Annals of Internal Medicine . . . . . . . 1808 American Medical Association . . . . . . 2720 Amgen. . . . . . . . . . . . . .1912,2318 Ankr Health . . . . . . . . . . . . . . 2533 Anumana................708 Arrowhead Pharmaceuticals . . . . . . . 1717 AskBio . . . . . . . . . . . . . . . 2312,B8 Association of Black Cardiologists . . . . 2715 AstraZeneca c/o TCEG . . . 1316, B23, B24, B25 AtriCure . . . . . . . . . . . . . . . .2415 Banner Health . . . . . . . . . . . . . .328 Bayer . . . . . . . . . . . . . . . 521, B13 BAYER AG . . . . . . . . . . . . . . B12, B15 Billings Clinic . . . . . . . . . . . . . . 424 Biobeat . . . . . . Health Innovation Pavilion BMS/J&J Alliance . . . . . . . . . .2514, B44 BMS/Pfizer . . . . . . . . . . . . . 712, B16 Boehringer Ingelheim Pharmaceuticals, Inc. . 2531 Boehringer Ingelheim/Lilly . . . . . . . .1109 Bridgebio . . . . . . . . . . . . . .526, B30 Bristol Myers Squibb . . . . . 902, B9, B47, B48 Bruker BioSpin . . . . . . . . . . . . . 2309 Cardiac Insight Inc. . Health Innovation Pavilion Cardio Flow Design Inc. . . . . . . . . . 2532 CardioTalk Theater I . . . . . . . . . . . 331 CardioTalk Theater II . . . . . . . . . . 2550 Carematix, Inc . . . . . . . . . . . . .1820 Caristo Diagnostics . . . . . . . . . . . 1714 CL Laboratory, LLC . . . . . . . . . . . 2527 Cleerly . . . . Health Innovation Pavilion, B14 Conquering CHD . . . . . . . . . . . .2712 Cytokinetics . . . . . . . . . . . . . .1312 Daiichi Sankyo, Inc. . . . . . . . . . . . 537 Decentralized Biotechnology Intelligence Co, LTD . . Health Innovation Pavilion DedicatedIT. . . . . . . . . . . . . .2554 Doximity . . . . . . . . . . . . . . . .706 Duke Clinical Research Institute . . . . . .702 Edwards Lifesciences . . . . . . . . . . 1921 Eko Health . . . . . . . . . . . . . . .1809 Eli Lilly and Company . . . . . . 914, B26, B35 Eli Lilly and Company Medical Affairs . . . 531 Elsevier, Inc. . . . . . . . . . . . . . . 2942 Esperion Therapeutics . . . . . . . . 1702, B17 Exemplar Genetics . . . . . . . . . . . .326 Family Heart Foundation . . . . . . . . 2222 FDA Center for Tobacco Products . . . . .2714 Foresee Pharmaceuticals . . . . . . . . 2316 Foundation for Sarcoidosis Research . . . 2815 FUJIFILM VisualSonics . . . . . . . . . .1708 Genomadix Inc. . . . . . . . . . . . . 2412 Getting to the Heart of Stroke . . . . . . .541 HealthSeers, Inc. . . Health Innovation Pavilion HeartBeam, Inc. . . . . . . . . . . . . 2313 HeartFlow . . . . . . . . . . . . . 1909, B31 HeartLung.AI . . . . . . . . . . . . . .2952 Hypertrophic Cardiomyopathy Association . . 809 Idorsia Pharmaceuticals US Inc. . . . . . 1705 Inspire Medical Systems, Inc. . . . . . . .2408 Intellia Therapeutics . . . . . . . . 2534, B27 Intermountain Health . . . . . . . . . . 909 Ionis Pharmaceuticals, Inc. . . . . . . . . 323 IonOptix . . . . . . . . . . . . . . . .2315 JAMA Network . . . . . . . . . . . . . 2943 Johnson & Johnson . . . . . . . . . . . . . . . .1902, B5, B6 Kaneka - LIPOSORBER . . . . . . . . . .1710 Kiniksa Pharmaceuticals . . . . . . .2224, B18 Kusmo.................710 LetsGetChecked . . . . . . . . . . . . 2413 Lexicon Pharmaceuticals, Inc. . . . . . . 2739 Lp(a)Testing . . . . . . . . . . . . . .2754 Mayo Clinic . . . . . . . . . . . . . . .716 McFarland Clinic . . . . . . . . . . . . . . . . . . . . . . . . .423 Medtronic . . . . . . . . . . . . . 1123, B45 Merck & Co., Inc. . . . . 1322, 1821, 917, B10, B11 Metabolic Endocrine Education Foundation . 2717 Mineralys Therapuetics, Inc. . . . . . . 427, B21 Moor Instruments . . . . . . . . . . . .2122 Nanion Technologies . . . . . . . . . . 2020 New Amsterdam Pharma . . . . . . 1112, B22 Nightingale Health Plc . . . . . . . . . 1920 Noah Labs . . . . . Health Innovation Pavilion Northwell Health . . . . . . . . . . . . 2409 Novartis Pharmaceuticals Corporation . 1302,1308 Novo Nordisk Inc . . . . . . . 2302, 2542, B19 Omron Healthcare, Inc . . . . . . . . . 2308 Patient Advocate Foundation . . . . . . 2718 Pfizer Inc. . . . . . . . . . . . . . 1115, B20 PPD™, part of Thermo Fisher Scientific . . .1720 Propria . . . . . . . . . . . . . . . . 2528 PuppySnuggles . . . . . . . . . . . . .320 Radcliff Cardiology . . . . . . . . . . . 921 Regeneron Pharmaceuticals, Inc. . . . .806, B7 Rep Pass . . . . . . . . . . . . . . . .2022 Research Diets, Inc. . . . . . . . . . . .2310 Rocket Pharmaceuticals, Inc. . . . . . . .2557 SANOFI . . . . . . . . . . . . . . . . . B28 scPharmaceuticals . . . . . . . . . . . . 426 SeeMedX . . . . . . . . . . . . . . . 2009 Silence Therapeutics . . . . . . . . . . 2109 Sky Labs . . . . . . Health Innovation Pavilion StopAfib.org . . . . . . . . . . . . . .2713 The Japanese Circulation Society . . . . . 2719 The National Heart, Lung, and Blood Institute . . . . . . . . . . .1721 TIMI Study Group . . . . . . . . . . . .2120 Ultrahuman Healthcare Private Limited . . 2526 Vantari VR . . . . . Health Innovation Pavilion VectorBuilder Inc. . . . . . . . . . . . . 808 Viatris . . . . . . . . . . . . . . . 2520, B2 VitalSight by Omron . Health Innovation Pavilion WoltersKluwer . . . . . . . . . . . . .2945 World Heart Federation . . . . . . . . . 2721 ZOLL Medical Corporation . . . . . . . . 1119 AHA HeartQuarters . . . . . Heart Hub 1 Global Quality Showcase . . Heart Hub 2 FAHA Lounge . . . . . . . . Heart Hub 3 Member Lounge . . . . . . Heart Hub 4 Health Innovation Pavilion . . Heart Hub 5 Simulation Zone . . . . . . Heart Hub 6 Heart Theater II . . . . . . Heart Hub 7 Learning Studio II . . . . . . Heart Hub 8 Charging Lounge . . . . . . Heart Hub 9 Learning Studio I Heart Hub 10 AHA Scholars Posters . . . . Heart Hub 11 Heart Theater I . . . . . . . Heart Hub 12 Located in the Heart Hub Scan the QR code for a list of First-Time Exhibitors at #AHA24
11 #AHA24 ScientificSessions.org Learn strategies to better manage VTE in your practice with our on-demand digital learning activities. These activities are supported by a medical education grant from the Bristol Myers Squibb and Pfizer Alliance. PAID ADVERTISEMENT Advancing Management and Care in Venous Thromboembolism (VTE) QA& Annual Dr. Nanette K. Wenger Research Goes Red® Award for Best Scientific Publication on Cardiovascular Disease and Stroke in Women 9:45-11 a.m. | Saturday, Nov. 16 S100A UPCOMING SESSION Shah Research Goes Red recognition Silvi Shah, MD, MS, will receive this year’s award honoring Dr. Nanette K. Wenger. In 2021, the American Heart Association established the Dr. Nanette K. Wenger Research Goes Red Award. The accolade, sponsored by the AHA’s Research Goes Red initiative, recognizes the best scientific article on cardiovascular disease and stroke in women that was published in an AHA journal. Silvi Shah, MD, MS, is this year’s recipient of the award, and she will present her article Saturday morning at Scientific Sessions. Shah is an associate professor in the Division of Nephrology and Hypertension at the University of Cincinnati College of Medicine. Scientific Sessions Daily News spoke with Shah to learn more about her background, research and awardwinning article, “Sex Differences in Cardiovascular Outcomes in Patients With Kidney Failure,” which was published in May in the Journal of the American Heart Association. The study was funded by a K23 career development award that Shah received from the National Institutes of Health. Q Congratulations on winning the Dr. Nanette K. Wenger Research Goes Red Award. What is the theme of your article, and what are some of the highlights that you will present during the session? Shah: Our study looked at sex differences in cardiovascular outcomes in patients with kidney failure who were receiving dialysis. Interestingly, we show that women, as compared to men, have a 14% higher risk of cardiovascular events, 16% higher risk of heart failure, 31% higher risk of stroke and no difference in risk of acute coronary syndrome. Our study is one of the first studies, to the best of our knowledge, to examine and report a higher risk of cardiovascular events in women among patients with kidney failure. Q Was there a specific experience or encounter that drove this investigation? Shah: Cardiovascular disease remains the leading cause of death in patients with kidney disease. Also, the risk of cardiovascular events is 10 to 20 times higher in patients with kidney failure as compared to the general population. I saw a 50-year-old female patient who had a history of kidney failure and was receiving hemodialysis at Cleveland Clinic. While evaluating her for possible transplantation, she asked how her cardiovascular risk differs by sex. Although sex differences in cardiovascular disease are well described in the general population, little is known about this among patients with kidney failure, which drove the initiation of the study. Q What is the importance of this research? Shah: Cardiovascular disease is the leading cause of death in women, and critical knowledge gaps continue to exist about women’s cardiovascular health, including sex differences in cardiovascular disease burden among patients receiving dialysis. Due to the high morbidity and mortality of cardiovascular disease in women and the paucity of data, the Research Goes Red initiative is essential.
12 SCIENTIFIC SESSIONS DAILY NEWS | Day 1 Saturday, Nov. 16, 2024 AHA selects six Distinguished Scientists for 2024 Robert O. Bonow, MD, MS, FAHA Northwestern University | Feinberg School of Medicine Chicago Robert O. Bonow is the Goldberg Distinguished Professor of Cardiology at the Northwestern University Feinberg School of Medicine. He was senior investigator and deputy chief of the cardiology branch of the National Heart, Lung, and Blood Institute at the National Institutes of Health from 1980 to 1992 and was chief of the division of cardiology at Northwestern University Feinberg School of Medicine from 1992 to 2011. His research focuses on the application of cardiovascular imaging to investigate the natural history and clinical outcomes of people with valvular heart disease, hypertrophic cardiomyopathy and ischemic left ventricular dysfunction. He has been author or co-author of over 650 papers in the medical literature and 120 book chapters. He is editor-in-chief of JAMA Cardiology and an editor of Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Bonow has served on the Board of Scientific Counselors and Board of Extramural Advisors of the NHLBI and the Subspecialty Board on Cardiovascular Disease of the American Board of Internal Medicine. He is a past president of the American Heart Association, a Master of the American College of Cardiology and a Master of the American College of Physicians. Among his honors are the NIH Director’s Award and the U.S. Public Health Service Commendation Medal and Outstanding Service Medal. He is a recipient of the Distinguished Leadership Award, Distinguished Achievement Award, Gold Heart Award and James B. Herrick Award of the AHA; the Distinguished Fellowship Award, Distinguished Service Award and Distinguished Scientist Award of the American College of Cardiology; and the John Phillips Memorial Award of the American College of Physicians. Pedro J. del Nido, MD, FAHA Boston Children’s Hospital Pedro J. del Nido has been at the forefront of myocardial preservation and more recently has focused on creating reconstructive techniques for complex congenital heart defects. Recognizing a large unmet need, del Nido has worked to develop cardiac medical devices The American Heart Association is honoring six professional members with its Distinguished Scientist award for extraordinary contributions to cardiovascular and stroke research. Following are the 2024 awardees. The 2024 awardees will be honored during the Opening Session on Saturday, Nov. 16. Exploring the Next Chapter in the Groundbreaking CRISPR Journey: Getting to the Heart of the Matter This event is not part of the official Scientific Sessions 2024 as planned by the American Heart Association Committee on Scientific Sessions Programming. Intellia Therapeutics, and the Intellia Therapeutics logo are trademarks of Intellia Therapeutics, Inc., registered in the U.S. Patent and Trademark Office and other jurisdictions. © 2024. Intellia Therapeutics, Inc. Copying of this material by any means without Intellia’s prior written consent is prohibited. 129-NTLA-2001-2024.8.27-v2 Jim Januzzi, MD Hutter Family Professor of Medicine in the Field of Cardiology, Harvard Medical School Chief Scientific Officer, Baim Institute for Clinical Research Cardiologist, Corrigan Minehan Heart Center, Massachusetts General Hospital Boston, Massachusetts CHAIR AND SPEAKER: Mathew Maurer, MD Professor of Medicine, Arnold and Arlene Goldstein Professor of Cardiology, Director of the Cardiac Amyloidosis Program NewYork-Presbyterian and Columbia University Irving Medical Center New York, New York Jonathan Phillips, PhD Head of Pharmacology & Toxicology Intellia Therapeutics Cambridge, Massachusetts SPEAKERS: American Heart Association 2024 Saturday, November 16, 2024 12:30 PM – 1:15 PM CST Lunch to be provided Learning Studio I McCormick Place Convention Center Chicago, Illinois Join leading experts as they examine the progressive burden of transthyretin amyloidosis on patients. Explore how CRISPR/Cas9-mediated gene editing could potentially address unmet treatment needs in cardiology. The discussion will also cover considerations for the management of transthyretin amyloidosis, illustrated through in-depth analyses of two patient case studies. INTELLIA THERAPEUTICS LEARNING STUDIO PAID ADVERTISEMENT
13 #AHA24 ScientificSessions.org designed for growing children. This effort has led to a novel growthaccommodating heart valve that is now in clinical trials. Del Nido was born in Santiago, Chile, and immigrated to the United States at age 10. He attended undergraduate and medical school at the University of WisconsinMadison. He completed a general surgery internship and residency at Boston University and entered cardiothoracic residency at the University of Toronto. Before starting his clinical training, he spent a year in the laboratory at the Banting Institute of the University of Toronto, where he began his work on myocardial preservation. That research focus continued through his residency and early career in congenital cardiac surgery. Del Nido spent an additional year as a clinical fellow at the Hospital for Sick Children in Toronto. He started his career at the University of Illinois Chicago then moved to the University of Pittsburgh, where he developed a solution to preserve the heart during prolonged heart surgery. This solution, now known as “del Nido cardioplegia,” is one of the most widely used cardioplegia formulations around the world. In 1994, del Nido joined the faculty at Boston Children’s Hospital and Harvard Medical School. He rose to the rank of professor of surgery and in 2004, he was named William E. Ladd Professor of Child Surgery at Harvard Medical School and cardiac surgeonin-chief at Boston Children’s. Del Nido has received NIH funding throughout his career. He has over 500 peer-reviewed publications and more than 50 awarded and pending patents. Jiang He, MD, PhD, MSc, FAHA Tulane University New Orleans Jiang He is an internationally renowned scientist in epidemiological, clinical and translational research in cardiometabolic diseases. He has been principal investigator and co-investigator for more than 50 major NIH research awards and has been an author of more than 750 scientific articles published in top-tier biomedical journals. He has led landmark studies that have documented: • Cardiovascular disease and cancer as the leading causes of death, with hypertension and cigarette smoking as the primary preventable risk factors for premature death in China. • The rapid acceleration of the global burden of obesity and diabetes, accompanied by large global disparities in hypertension. • The increased risk of cardiovascular disease and allcause mortality associated with high sodium intake in people with obesity or chronic kidney disease. • The safety of early antihypertensive treatment in people with acute ischemic stroke. • The effectiveness of an intervention led by community health workers to lower blood pressure, improve hypertension control and significantly reduce cardiovascular events, all-cause dementia and total mortality. These study findings contribute to cardiometabolic disease prevention in resourceconstrained populations globally. He is a dedicated educator who has mentored more than 100 master’s students and more than 50 doctoral students and postdoctoral fellows. He has also mentored over 20 junior faculty investigators, many of whom have developed successful research careers and become leaders in their fields. He has received numerous awards from local, national and international academic institutions and professional societies, including the Distinguished Alumnus Award from Johns Hopkins University, Research Hall of Fame induction from Tulane University, the Detlev Ganten Excellence Award in Hypertension and Global Health Implementation from the World Hypertension League, and the Abraham Lilienfeld Award from the American College of Epidemiology. See AWARDS, page 14 Please join us for a special presentation on data generation and select methodologies that can help inform clinical practice MOVING BEYOND CLINICAL TRIALS: UNDERSTANDING REAL-WORLD EVIDENCE IN VENOUS THROMBOEMBOLISM (VTE) November 17, 2024 9:30-10:30 am CST Learning Studio II Please book your calendar to join us: FACULTY PRESENTERS: TOPICS OF DISCUSSION: • The use of randomized controlled trials (RCTs) and real-world evidence (RWE) • Select methodologies for conducting and analyzing real-world studies • Examples of real-world observational studies of select anticoagulants in patients with VTE This event is not part of the official Scientific Sessions 2024 as planned by the American Heart Association Committee on Scientific Sessions Program © 2024 Bristol-Myers Squibb Company CV-US-2400256 09/2024 Steven B. Deitelzweig MD, MMM, FACC, SFHM, FACP, RVT System Chairman, Hospital Medicine Medical Director of Regional Business Development, Ochsner Health Professor of Medicine, University of Queensland and Ochsner Clinical School W. Frank Peacock MD, FACEP, FACC, FESC Professor and Vice Chair of Research at the Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine Paid Advertisement CV-US-2400256_AHA_Junior-Pg_Journal_Ad_R02.indd 1 10/9/24 10:37 AM
14 SCIENTIFIC SESSIONS DAILY NEWS | Day 1 Saturday, Nov. 16, 2024 In 2023, He was elected to the National Academy of Medicine for transforming cardiovascular disease prevention efforts worldwide. Debra K. Moser, PhD, RN, FAHA University of Kentucky Lexington, Kentucky Debra K. Moser is a professor at the University of Tennessee, and professor and Linda C. Gill Chair of Cardiovascular Nursing at the University of Kentucky. She is director of the Research and Interventions for Cardiovascular Health (RICH) Heart Program, an international research collaborative dedicated to cardiovascular research and mentorship. She is also an editor of the Journal of Cardiovascular Nursing. Her research program focuses on intervention research and testing biobehavioral self-care interventions in populations with notable health disparities, including rural residents, caregivers and other vulnerable people with cardiovascular disease and heart failure to improve quality of life, morbidity and mortality. She also studies cardiovascular risk reduction in rural residents at high risk for CVD and heart failure. Examining the impact of depressive symptoms on outcomes is an underpinning of all her work. Moser’s work has been recognized with more than 30 awards, including the HFSA Lifetime Achievement Award, the Dracup mentorship, Lembright as well as Heart Failure Research awards from the American Heart Association. She has been recognized with the President’s Research Award from Friends of the National Institute of Nursing Research. She is a fellow of the American Academy of Nursing, the AHA and the Preventive Cardiovascular Nurses Association. Her funding from the National Institutes of Health and the Patient-Centered Outcomes Research Institute exceeds $40 million. She has published more than 450 data-based journal articles, 25 chapters and three books. Jane W. Newburger, MD, MPH, FAHA Harvard Medical School Boston Jane W. Newburger is the Commonwealth Professor of Pediatrics at Harvard Medical School and associate cardiologist-inchief for academic affairs at Boston Children’s Hospital. An international authority in pediatric cardiovascular disease, Newburger has focused her research on clinical outcomes and neurodevelopment in congenital heart disease, Kawasaki disease and the multisystem inflammatory syndrome in children. She has published over 600 peer-reviewed manuscripts, reviews and chapters. She is a member of the National Academy of Medicine and has received the Distinguished Scientist Award (Clinical) of the American College of Cardiology, the Clinical Research Prize of the American Heart Association, the AHA Young Hearts Meritorious Achievement Award, the AHA Paul Dudley White Award and the Helen Taussig Founders Award of the American Academy of Pediatrics. Newburger has served on the National Heart, Lung, and Blood Institute Advisory Council, leadership councils in the AAP, ACC and AHA, and the board of trustees of the ACC. She previously chaired the Clinical Science Subcommittee of the NHLBI Task Force on Pediatric Cardiovascular Disease and the AHA Rheumatic Fever, Endocarditis and Kawasaki Disease Committee. She is a former associate editor and then senior editor of the AHA’s flagship journal, Circulation, and currently serves on an array of journal editorial boards. She has mentored generations of trainees and junior faculty; is a longstanding PI of a T32 award in pediatric cardiovascular research; and received both the Harvard Medical School’s William Silen Lifetime Achievement in Mentoring Award and the Joseph B. Martin Dean’s Leadership Award for the Advancement of Women Faculty. AWARDS continued from page 13
15 #AHA24 ScientificSessions.org Newburger has been continuously funded by the National Institutes of Health since 1982. Her weighted Relative Citation Ratio is 2250, and she has 33 published manuscripts above the 99th NIH percentile for citation. She also maintains a busy clinical practice comprising patients with congenital and acquired heart disease, keeping her grounded regarding important issues affecting the wellbeing of children with heart disease. Stephen G. Young, MD, FAHA University of California, Los Angeles Stephen G. Young is an American physician-scientist known for investigating the genetics and molecular physiology of apolipoprotein B, the intravascular processing of triglyceride-rich lipoproteins by lipoprotein lipase, and the role of nuclear lamins in health and disease. Young is a distinguished professor of medicine and human genetics at UCLA, where he has worked closely with two faculty colleagues (Loren G. Fong, PhD, and Anne P. Beigneux, PhD). Young defined the first APOB mutations causing familial hypobetalipoproteinemia. He discovered that GPIHBP1, a protein of capillary endothelial cells, is crucial for the lipolytic processing of triglyceriderich lipoproteins. GPIHBP1 captures LPL from within the interstitial spaces (where it is secreted by myocytes) and shuttles it across endothelial cells to its site of action within the capillary lumen. In the absence of GPIHBP1, LPL is stranded within the interstitial spaces, resulting in markedly impaired intravascular triglyceride hydrolysis and severe hypertriglyceridemia. He also demonstrated that hypertriglyceridemia in the setting of APOA5 deficiency is caused by reduced amounts of LPL inside capillaries. APOA5 suppresses the ability of the ANGPTL3/ANGPTL8 complex to detach LPL from its binding sites within capillaries. Young studied the history of science at Princeton University and earned a medical degree from Washington University in St. Louis. He trained in internal medicine at the University of California, San Francisco, and cardiovascular diseases at the University of California, San Diego. He is boardcertified in both disciplines. He is a member of the National Academy of Sciences, the American Society for Clinical Investigation and the Association of American Physicians. He is a corresponding member abroad of the Austrian Academy of Sciences and was named an inaugural fellow of the American Society for Biochemistry and Molecular Biology. He has received a Jung Prize in Medicine and an honorary doctorate in medicine from the University of Gothenburg in Sweden. Visit professional.heart.org/en/ meetings/scientific-sessions/ awards for council award recognition. Pick up your copy near the Science & Technology Hall entrance, or scan the QR codes to view online. Take a through Customized agendas for Scientific Sessions 2024
RkJQdWJsaXNoZXIy MjI2NjI=